Anticancer drugs : reactive metabolism and drug interactions
著者
書誌事項
Anticancer drugs : reactive metabolism and drug interactions
（International encyclopedia of pharmacology and therapeutics, section 141）
Pergamon Press, 1994
大学図書館所蔵 件 / 全15件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
内容説明・目次
内容説明
There are over 50 clinically approved anticancer drugs, as well as numerous steroidal agents, and in addition there are many new anticancer drugs in various stages of preclinical and clinical development. The anticancer drugs embody a diverse array of chemical structures. The purpose of this two-volume publication is to provide a comprehensive review of the metabolism of anticancer drugs. The authors, each expert in their fields, have attempted to emphasize the relation of metabolism to the therapeutic and toxic effects of anticancer drugs, drawing whenever possible on human studies. There is a critical need for new approaches to treating cancer and it is certain that we will see an increasing number of new drugs with exotic chemical structures used for chemotherapy and perhaps chemoprevention. To understand the mechanism of action of any drug it is important to know how the drug is transformed in the body, either into active metabolites or inactive products to be excreted. With this information the success or failure of a drug in arresting cancer cell growth can be assessed, and perhaps more effective drugs designed.
Medical science has taken the first important steps toward controlling cancer. The use and study of current chemotherapeutic drugs has taught us much about how toxic chemicals can be employed to treat human cancer; comprehending the underlying metabolism of these drugs should facilitate even better modalities of treatment for the future.
目次
- Part 1 Metabolism and reactions of alkylating agents, P.B. Farmer: nitrogen mustard (mechlorethamine)
- prednismustine
- estramustine phosphate
- azo-mustards
- aniline mustard
- aziridinyl benzoquinones
- hexitol derivatives. Part 2 Metabolism and pharmacokinetic behaviour of cyclophosphamide and related oxazaphosphorines, N.E. Sladek: rationale for synthesis
- pharmacokinetics
- mechanism of cytotoxic action
- modulation of cyclophosphamide metabolism and the therapeutic consequences. Part 3 Metabolism of triazine anticancer agents, M. D'Incalci: metabolism and pharmacokinetics in different animal species
- drug interactions. Part 4 The metabolism of triazene antitumor drugs, M.D. Threadgill and A. Gescher: oxidative metabolism of 1-aryl-3, 3-dialkyltriazenes at the alkyl groups
- the role of metabolism in the mechanisms of toxicity, mutagenicity and carcinogenicity of triazenes. Part 5 The metabolism and mode of action of 2-chloroethylnitrosoureas, D.J. Reed: historical background
- metabolism
- animal studies
- CNCC metabolism
- the future. Part 6 Metabolism of the hydrazine anti-cancer agent, procarbazine, J.M. Erickson et al: antitumor activity
- toxicity
- factors modulating anticancer activity. Part 7 Chemical reactions occurring between metal-containing antineoplastic drugs and biological molecules, C.L. Litterst: metallocene. Part 8 Metabolism and reactions of quinoid anticancer agents, G. Powis: simple quinoids
- mitomycins
- streptonigrins. Part 9 Bleomycin hydrolase and tumor resistance to bleomycin, S.M. Sebti and J.S. Lazo. Part 10 Metabolic basis for the chemosensitization to anticancer drug action by nitroimidazoles, F.Y.F. Lee and P. Workman: metabolic basis of chemosensitization. Part 11 Effects of cancer disease on the metabolism of anticancer agents, S. Garratini et al: clinical studies. Part 12 Effects of anticancer drugs on drug metabolism, J. Aarbakke and L. Slordal: interactions by anticancer drugs.
「Nielsen BookData」 より
